SCHEMBL13629424

SCHEMBL13629424

CCc1ccc(NS(=O)(=O)c2c(Cl)cccc2Cl)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
LMNA P02545 3/20 0.62
ATM Q13315 1/20 0.52
GAA P10253 2/20 0.50
PKM P14618 3/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
IDH1 O75874 1/20 0.42
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CDK7 P50613 1/20 0.42
CCNH P51946 1/20 0.42
CCNA1 P78396 1/20 0.42
TP53 P04637 1/20 0.41
HTT P42858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17174223 0.85 PKM (0.64) ALDH1A1LMNAATMGAAPKM
SCHEMBL13629401 0.85 ALDH1A1 (0.65) ALDH1A1LMNAPKMMEN1KMT2A
SCHEMBL13629427 0.84 ALDH1A1 (0.54) ALDH1A1LMNAATMGAAPKM
SCHEMBL13629320 0.84 SLC22A12 (0.54) ALDH1A1LMNAGAAMEN1KMT2A
SCHEMBL13852925 0.81 PKM (0.75) ALDH1A1LMNAPKMMAPTALOX15
SCHEMBL13615132 0.79 ALDH1A1 (0.57) ALDH1A1LMNAATMGAAPKM
SCHEMBL13629423 0.78 CES1 (0.60) ALDH1A1GAAPKMMAPT
SCHEMBL13629553 0.78 PKM (0.56) ALDH1A1LMNAPKMMAPTPGR
SCHEMBL13629329 0.78 ALDH1A1 (0.65) ALDH1A1LMNAMAPTIDH1CDK1
SCHEMBL13629416 0.77 ALDH1A1 (0.60) ALDH1A1LMNAGAAPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885LMNA 2891/4885ATM 564/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885LMNA 2608/4885ATM 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.